The multiple sites could be strategic for Phase 3 planning... CRO would have those sites registered for a trial... Other than that, I'm not sure why they would need more than 10 to 12?
It seems plausible that the trial is a ph2/3. The first part of the trial is 106 patients in Russia with interim data after the 106th patient completes treatment. Then the trial expands into the USA while continuing to enroll in Russia. Thoughts? I know the Russian clinical trials website states a "phase 2", however in the extension doc (NT Q-10) Part III Narrative, it clearly states "trials" - plural.
News 
Market Data 
Discover 
AI
